Advanced search
Publication Cover
Future Oncology Volume 19, 2023 - Issue 9
Submit an article Journal homepage
94
Views
0
CrossRef citations to date
0
Altmetric
Editorial

NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned?

Rita Khoury1 Division of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, 94800, France
,
Rebecca Ibrahim1 Division of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, 94800, France
,
Tony Ibrahim1 Division of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, 94800, France
,
Axel Le Cesne1 Division of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, 94800, France
&
Tarek Assi1 Division of International Patients Care, Gustave Roussy Cancer Campus, Villejuif, 94800, FranceCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-5579-5264
ORCID Icon
Pages 617-620 | Received 01 Feb 2023, Accepted 06 Mar 2023, Published online: 02 May 2023

References

  • Surveillance, Epidemiology, and End Results . Cancer of the pancreas – cancer stat facts, 2023. https://seer.cancer.gov/statfacts/html/pancreas.html
  • Ghosn M , IbrahimT, AssiT, ElRassy E, KourieHR, KattanJ. Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. World J. Gastroenterol.22(46), 10124 (2016).
  • Burris HA , MooreMJ, AndersenJet al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol.15(6), 2403–2413 (1997).
  • Conroy T , DesseigneF, YchouMet al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med.364(19), 1817–1825 (2011).
  • Von Hoff DD , ErvinT, ArenaFPet al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med.369(18), 1691–1703 (2013).
  • Klein-Brill A , Amar-FarkashS, LawrenceG, CollissonEA, AranD. Comparison of FOLFIRINOX vs gemcitabine plus nab-paclitaxel as first-line chemotherapy for metastatic pancreatic ductal adenocarcinoma. JAMA Netw. Open5(6), e2216199 (2022).
  • Hegewisch-Becker S , AldaoudA, WolfTet al. Results from the prospective German TPK clinical cohort study: treatment algorithms and survival of 1,174 patients with locally advanced, inoperable, or metastatic pancreatic ductal adenocarcinoma. Int. J. Cancer144(5), 981–990 (2019).
  • Muranaka T , KuwataniM, KomatsuYet al. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. J. Gastrointest. Oncol.8(3), 566–571 (2017).
  • Hollmann S , AlloulK, AttardC, KavanP. An indirect treatment comparison and cost-effectiveness analysis comparing folfirinox with nab-paclitaxel plus gemcitabine for first-line treatment for patients with metastatic pancreatic cancer. Ann. Oncol.25(Suppl. 2), Abstract II11 (2014).
  • Akbarzadeh A , Rezaei-SadabadyR, DavaranSet al. Liposome: classification, preparation, and applications. Nanoscale Res. Lett.8(1), 102 (2013).
  • Sachdev JC , MunsterP, NorthfeltDWet al. Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase. Breast Cancer Res. Treat.185(3), 759–771 (2021).
  • Chiang N-J , ChaoT-Y, HsiehR-Ket al. A phase I dose-escalation study of PEP02 (irinotecan liposome injection) in combination with 5-fluorouracil and leucovorin in advanced solid tumors. BMC Cancer16(1), 907 (2016).
  • Ko AH , TemperoMA, ShanY-Set al. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br. J. Cancer109(4), 920–925 (2013).
  • Wang-Gillam A , LiC-P, BodokyGet al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet387(10018), 545–557 (2016).
  • Frampton JE . Liposomal irinotecan: a review in metastatic pancreatic adenocarcinoma. Drugs80(10), 1007–1018 (2020).
  • Ducreux M , CuhnaAS, CaramellaCet al. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.26(Suppl. 5), v56–68 (2015).
  • Sohal DPS , KennedyEB, KhoranaAet al. Metastatic pancreatic cancer: ASCO Clinical Practice Guideline Update. J. Clin. Oncol.36(24), 2545–2556 (2018).
  • Wainberg ZA , Bekaii-SaabT, BolandPMet al. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: a phase I/II study. Eur. J. Cancer151, 14–24 (2021).
  • Wainberg ZA , Bekali-SaabTS, HubnerRet al. NAPOLI-3: an open-label, randomized, phase III study of first-line liposomal irinotecan+5-fluorouracil/leucovorin+oxaliplatin versus nab-paclitaxel+gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma. J. Clin. Oncol.38(Suppl. 15), TPS4661 (2020).
  • Chun JW , LeeSH, KimJSet al. Comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel including sequential treatment for metastatic pancreatic cancer: a propensity score matching approach. BMC Cancer21(1), 537 (2021).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.